

# James G Krueger

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4203377/james-g-krueger-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313  
papers

30,929  
citations

96  
h-index

170  
g-index

327  
ext. papers

36,693  
ext. citations

5.8  
avg. IF

7.41  
L-index

#	Paper	IF	Citations
313	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis.. <i>American Journal of Clinical Dermatology</i> , <b>2022</b> ,	7.1	5
312	A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. <i>Experimental Dermatology</i> , <b>2021</b> , 30, 1388-1397	4	7
311	A Randomized Open Label Clinical Trial of Lipid-Lowering Therapy in Psoriasis to Reduce Vascular Endothelial Inflammation. <i>Journal of Investigative Dermatology</i> , <b>2021</b> ,	4.3	4
310	Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	4
309	Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	4
308	Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Transcriptomics from a Phase 2a Randomized, Multicenter Double-Blinded Study. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	2
307	Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 1306-1315	5.1	0
306	Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e204-e213	14.2	5
305	Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1670-1680	15.1	9
304	Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 1281-1292	11.5	7
303	High-dimensional analysis defines multicytokine T-cell subsets and supports a role for IL-21 in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 3080-3093	9.3	1
302	Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways. <i>British Journal of Dermatology</i> , <b>2021</b> , 185, 585-594	4	7
301	Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 3107-3121	9.3	6
300	Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 2213-2224	11.5	13
299	The Busy Arena of Psoriasis Treatments: Improving the Clinician's Ability to Make the Right Therapeutic Choice. <i>American Journal of Clinical Dermatology</i> , <b>2021</b> , 22, 731-733	7.1	0
298	An integrated scalp and blood biomarker approach suggests the systemic nature of alopecia areata. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 3053-3065	9.3	0
297	Tyrosine kinase 2 and Janus kinase-signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> ,	4.5	10

296	Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 370-380	4.5	13
295	Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 688-696	4	11
294	Tape strips from early-onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 314-325	9.3	21
293	Characterization of PCSK9 in the Blood and Skin of Psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 308-315	4.3	8
292	Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1369-1380	11.5	11
291	Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. <i>British Journal of Dermatology</i> , <b>2021</b> , 184, 350-352	4	8
290	SARS-CoV-2 receptor ACE2 protein expression in serum is significantly associated with age. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 875-878	9.3	21
289	Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 199-212	11.5	35
288	Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1107-1109.e2	11.5	8
287	CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 913-920	4.5	6
286	The erythema Q-score, an imaging biomarker for redness in skin inflammation. <i>Experimental Dermatology</i> , <b>2021</b> , 30, 377-383	4	2
285	Tape-strips provide a minimally invasive approach to track therapeutic response to topical corticosteroids in atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 576-579.e3	5.4	7
284	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. <i>Lancet, The</i> , <b>2021</b> , 397, 475-486	4 <sup>0</sup>	44
283	The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 148-163	11.5	14
282	Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa. <i>British Journal of Dermatology</i> , <b>2021</b> ,	4	2
281	IL-36 and IL-17A Cooperatively Induce a Psoriasis-Like Gene Expression Response in Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2086-2090	4.3	1
280	Transcriptomic Profiling of Tape-Strips From Moderate to Severe Atopic Dermatitis Patients Treated With Dupilumab. <i>Dermatitis</i> , <b>2021</b> , 32, S71-S80	2.6	1
279	Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> , 35, e884-e887	4.6	0

278	T 2 cytokines and Staphylococcus aureus cooperatively induce atopic dermatitis-like transcriptomes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 76, 3534-3537	9.3	0
277	Response to Rack of efficacy of dupilumab in the treatment of keloid disorder Pby MH Tirgan and J Uitto. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2021</b> ,	4.6	
276	Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 141, 111950	7.5	2
275	In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. <i>Journal of Investigative Dermatology</i> , <b>2021</b> , 141, 2197-2207	4.3	8
274	Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2021</b> , 127, 334-341	3.2	1
273	Phase 2a randomized clinical trial of dupilumab (anti-IL-4R $\beta$ ) for alopecia areata patients. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	9.3	10
272	Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design. <i>JAAD International</i> , <b>2020</b> , 1, 208-221	0.9	3
271	NFI transcription factors provide chromatin access to maintain stem cell identity while preventing unintended lineage fate choices. <i>Nature Cell Biology</i> , <b>2020</b> , 22, 640-650	23.4	14
270	Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets?. <i>Experimental Dermatology</i> , <b>2020</b> , 29, 509-515	4	7
269	Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 1083-1093	4	14
268	Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, 1340-1351	9.4	23
267	Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1615-1628	11.5	98
266	The aging skin microenvironment dictates stem cell behavior. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 5339-5350	11.5	32
265	Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1546-1555.e4	4.3	21
264	Comparing cutaneous molecular improvement with different treatments in atopic dermatitis patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1285-1288	11.5	10
263	A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue. <i>Oncotarget</i> , <b>2020</b> , 11, 2587-2596	3.3	7
262	Deep learning-level melanoma detection by interpretable machine learning and imaging biomarker cues. <i>Journal of Biomedical Optics</i> , <b>2020</b> , 25,	3.5	3
261	The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1341-1348	4.5	31

260	Early Quantification of Systemic Inflammatory Proteins Predicts Long-Term Treatment Response to Tofacitinib and Etanercept. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1026-1034	4.3	11
259	Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 124, 70-78	3.2	28
258	Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. <i>British Journal of Dermatology</i> , <b>2020</b> , 182, 1045-1047	4	16
257	The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 690-699	4.5	43
256	Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 82, 1150-1157	4.5	29
255	Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 922-932	11.5	11
254	Persistence of Inflammatory Phenotype in Residual Psoriatic Plaques in Patients on Effective Biologic Therapy. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 1015-1025.e4	4.3	5
253	Keloid lesions show increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2020</b> , 34, e161-e164	4.6	16
252	Improving evaluation of drugs in atopic dermatitis by combining clinical and molecular measures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3622-3625.e19	5.4	6
251	A Preliminary F-FDG-PET/MRI Study Shows Increased Vascular Inflammation in Moderate-to-Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3500-3506	5.4	2
250	Obesity and ethnicity alter gene expression in skin. <i>Scientific Reports</i> , <b>2020</b> , 10, 14079	4.9	1
249	RNA Sequencing Keloid Transcriptome Associates Keloids With Th2, Th1, Th17/Th22, and JAK3-Skewing. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 597741	8.4	13
248	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , <b>2020</b> , 10, e039928	3	0
247	Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 215-228	11.5	33
246	IL-4R $\beta$ Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , <b>2020</b> , 140, 191-202.e7	4.3	57
245	Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 1011-1024	11.5	54
244	Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2158-2169	11.5	31
243	Inter-rater reliability of phenotypes and exploratory genotype-phenotype analysis in inherited hidradenitis suppurativa. <i>British Journal of Dermatology</i> , <b>2019</b> , 181, 566-571	4	25

242	Hyperspectral imaging in automated digital dermoscopy screening for melanoma. <i>Lasers in Surgery and Medicine</i> , <b>2019</b> , 51, 214-222	3.6	20
241	The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 510-519	4.5	39
240	Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa/ acne inversa. <i>Experimental Dermatology</i> , <b>2019</b> , 28, 886-891	4	17
239	A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin 17A/F nanobody, in moderate-to-severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 196-203	4.5	27
238	The skin as an immune organ: Tolerance versus effector responses and applications to food allergy and hypersensitivity reactions. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 362-374	11.5	22
237	Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. <i>Therapeutic Advances in Chronic Disease</i> , <b>2019</b> , 10, 2040622319830648	4.9	35
236	Age-specific changes in the molecular phenotype of patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 144-156	11.5	46
235	Inflammasome Signaling and Impaired Vascular Health in Psoriasis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2019</b> , 39, 787-798	9.4	33
234	Ichthyosis molecular fingerprinting shows profound T17 skewing and a unique barrier genomic signature. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 604-618	11.5	37
233	Cutaneous p38 mitogen-activated protein kinase activation triggers psoriatic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 1036-1049	11.5	17
232	Major Differences in Expression of Inflammatory Pathways in Skin from Different Body Sites of Healthy Individuals. <i>Journal of Investigative Dermatology</i> , <b>2019</b> , 139, 2228-2232.e10	4.3	9
231	IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 750-763	11.5	45
230	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 394, 576-586	40	121
229	Use of Tape Strips to Detect Immune and Barrier Abnormalities in the Skin of Children With Early-Onset Atopic Dermatitis. <i>JAMA Dermatology</i> , <b>2019</b> , 155, 1358-1370	5.1	56
228	Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1965-1969	11.5	16
227	Atopic dermatitis in African American patients is T2/T22-skewed with T1/T17 attenuation. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2019</b> , 122, 99-110.e6	3.2	72
226	Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 142-154	11.5	80
225	Atopic dermatitis endotypes and implications for targeted therapeutics. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1-11	11.5	198

224	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 155-172	11.5	246
223	Blood endotyping distinguishes the profile of vitiligo from that of other inflammatory and autoimmune skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 2095-2107	11.5	24
222	Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin. <i>Experimental Dermatology</i> , <b>2019</b> , 28, 35-44	4	5
221	Distinct transcriptomic profiles of early-onset atopic dermatitis in blood and skin of pediatric patients. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2019</b> , 122, 318-330.e3	3.2	18
220	The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 197-205	3.9	40
219	Serum from Asian patients with atopic dermatitis is characterized by T2/T22 activation, which is highly correlated with nonlesional skin measures. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 324-328.e11	11.5	33
218	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , <b>2018</b> , 78, 872-881.e6	4.5	172
217	Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease <b>2018</b> , 133-144		
216	The Major Orphan Forms of Ichthyosis Are Characterized by Systemic T-Cell Activation and Th-17/Tc-17/Th-22/Tc-22 Polarization in Blood. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 2157-2167	4.3	21
215	Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. <i>Therapeutic Advances in Chronic Disease</i> , <b>2018</b> , 9, 111-119	4.9	56
214	Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. <i>Experimental Dermatology</i> , <b>2018</b> , 27, 409-417	4	92
213	Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 273-281	4.3	30
212	The human CIB1-EVER1-EVER2 complex governs keratinocyte-intrinsic immunity to Epapillomaviruses. <i>Journal of Experimental Medicine</i> , <b>2018</b> , 215, 2289-2310	16.6	56
211	An integrated model of alopecia areata biomarkers highlights both T1 and T2 upregulation. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1631-1634.e13	11.5	21
210	Atopic dermatitis in Chinese patients shows T2/T17 skewing with psoriasiform features. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1013-1017	11.5	37
209	Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1010-1013.e6	11.5	20
208	Early-onset pediatric atopic dermatitis is characterized by T2/T17/T22-centered inflammation and lipid alterations. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 2094-2106	11.5	106
207	Proportion of CD4CD49bLAG-3 Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 2669-2672	4.3	16

206	A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa. <i>F1000Research</i> , <b>2018</b> , 7, 1930	3.6	51
205	A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa. <i>F1000Research</i> , <b>2018</b> , 7, 1923	3.6	17
204	A systematic review and critical evaluation of immunohistochemical associations in hidradenitis suppurativa. <i>F1000Research</i> , <b>2018</b> , 7, 1923	3.6	7
203	Enhancement of cutaneous immunity during aging by blocking p38 mitogen-activated protein (MAP) kinase-induced inflammation. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 844-856	11.5	46
202	Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. <i>Experimental Dermatology</i> , <b>2018</b> , 27, 115-123	4	61
201	Impact of Zostavax Vaccination on T-Cell Accumulation and Cutaneous Gene Expression in the Skin of Older Humans After Varicella Zoster Virus Antigen-Specific Challenge. <i>Journal of Infectious Diseases</i> , <b>2018</b> , 218, S88-S98	7	8
200	Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. <i>Journal of Immunology</i> , <b>2018</b> , 201, 1605-1613	5.3	213
199	IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2018</b> , 138, 1467-1469	4.3	38
198	IL-32 induces indoleamine 2,3-dioxygenase CD1c dendritic cells and indoleamine 2,3-dioxygenase CD163 macrophages: Relevance to mycosis fungoides progression. <i>Oncol Immunology</i> , <b>2017</b> , 6, e1181237	7.2	20
197	Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 28-35	4	136
196	Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism. <i>Nature</i> , <b>2017</b> , 543, 252-256	50.4	336
195	TNF- $\alpha$ Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled Study. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 1638-1645	4.3	56
194	Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab. <i>JAMA Dermatology</i> , <b>2017</b> , 153, 299-303	5.1	74
193	Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10. <i>Journal of Immunology</i> , <b>2017</b> , 198, 3809-3814	5.3	45
192	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 1551-1560	59.2	306
191	Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 1075-1082 <sup>4</sup>		61
190	Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 679-683	4.1	1
189	Autoimmunity in Psoriasis: Evidence for Specific Autoantigens. <i>Current Dermatology Reports</i> , <b>2017</b> , 6, 104-112	1.5	4



188	Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1723-1734	11.5	154
187	Aberrant connective tissue differentiation towards cartilage and bone underlies human keloids in African Americans. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 721-727	4	12
186	Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 134-144.e9	11.5	34
185	Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing $\gamma$ cell clones. <i>Journal of Clinical Investigation</i> , <b>2017</b> , 127, 4031-4041	15.9	134
184	The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. <i>Scientific Reports</i> , <b>2017</b> , 7, 8707	4.9	104
183	Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. <i>Current Opinion in Immunology</i> , <b>2017</b> , 48, 68-73	7.8	169
182	Psoriasis pathogenesis and the development of novel targeted immune therapies. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 645-653	11.5	400
181	IFN $\gamma$ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. <i>Cell</i> , <b>2017</b> , 170, 127-141.e15	56.2	104
180	Response to Hjuler et al. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 2237-2238	4.3	
179	Digital imaging biomarkers feed machine learning for melanoma screening. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 615-618	4	22
178	An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 603-613	4.3	102
177	MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 775-778	4.3	9
176	Patch testing of food allergens promotes Th17 and Th2 responses with increased IL-33: a pilot study. <i>Experimental Dermatology</i> , <b>2017</b> , 26, 272-275	4	9
175	An IL-17-dominant immune profile is shared across the major orphan forms of ichthyosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 152-165	11.5	81
174	Shrinking the Psoriasis Assessment Gap: Early Gene-Expression Profiling Accurately Predicts Response to Long-Term Treatment. <i>Journal of Investigative Dermatology</i> , <b>2017</b> , 137, 305-312	4.3	34
173	Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. <i>Journal of Dermatological Science</i> , <b>2017</b> , 85, 20-26	4.3	23
172	Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis. <i>Annual Review of Medicine</i> , <b>2017</b> , 68, 255-269	17.4	97
171	Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 562-571	11.5	71

170	Psoriasis and Other Skin Inflammatory Diseases <b>2017</b> , 1091-1104		1
169	Line scanning, stage scanning confocal microscope (LSSSCM). <i>Biomedical Optics Express</i> , <b>2017</b> , 8, 3807-3815		9
168	The management of moderate-to-severe chronic plaque psoriasis. <i>Italian Journal of Dermatology and Venereology</i> , <b>2017</b> , 152, 447-457	1.2	1
167	Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 118-129.e5	11.5	70
166	Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22. <i>JCI Insight</i> , <b>2016</b> , 1, e86434	9.9	25
165	Biomarkers of alopecia areata disease activity and response to corticosteroid treatment. <i>Experimental Dermatology</i> , <b>2016</b> , 25, 282-6	4	42
164	Lipoprotein Metabolism and Inflammation in Patients With Psoriasis. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 603-9	3	22
163	Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1079-1090	11.5	89
162	Reply. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 318-320	11.5	
161	New therapies for psoriasis and psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 204-10	5.3	52
160	Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 301-304	11.5	48
159	A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 169-178	11.5	54
158	The tryptophan metabolism enzyme L-kynureninase is a novel inflammatory factor in psoriasis and other inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1830-1840	11.5	63
157	Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1091-1102.e7	11.5	92
156	Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 161-172	4.3	36
155	Based on Molecular Profiling of Gene Expression, Palmoplantar Pustulosis and Palmoplantar Pustular Psoriasis Are Highly Related Diseases that Appear to Be Distinct from Psoriasis Vulgaris. <i>PLoS ONE</i> , <b>2016</b> , 11, e0155215	3.7	26
154	Cutaneous Expression of A Disintegrin-like and Metalloprotease domain containing Thrombospondin Type 1 motif-like 5 (ADAMTSL5) in Psoriasis goes beyond Melanocytes. <i>Journal of Pigmentary Disorders</i> , <b>2016</b> , 3,		18
153	Molecular and Cellular Profiling of Scalp Psoriasis Reveals Differences and Similarities Compared to Skin Psoriasis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148450	3.7	23

152	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , <b>2016</b> , 25, 553-4	4	11
151	Discrimination of Dysplastic Nevi from Common Melanocytic Nevi by Cellular and Molecular Criteria. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 2030-2040	4.3	23
150	The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 2173-2182	4.3	27
149	Methotrexate improves pro- and anti-atherogenic genomic expression in psoriatic skin. <i>Journal of Dermatological Science</i> , <b>2016</b> , 82, 207-9	4.3	3
148	Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1473-1477.e5	11.5	24
147	Early-onset pediatric atopic dermatitis is T2 but also T17 polarized in skin. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1639-1651	11.5	203
146	Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis. <i>Advances in Therapy</i> , <b>2016</b> , 33, 1231-45	4.1	29
145	Molecular Profiling of Immune Activation Associated with Regression of Melanoma Metastases Induced by Diphencyprone. <i>Journal of Investigative Dermatology</i> , <b>2016</b> , 136, 2101-2103	4.3	3
144	Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. <i>British Journal of Dermatology</i> , <b>2016</b> , 174, 136-45	4	54
143	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 273-86	4	297
142	Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 104-115.e7	11.5	130
141	The immunogenetics of Psoriasis: A comprehensive review. <i>Journal of Autoimmunity</i> , <b>2015</b> , 64, 66-73	15.5	326
140	CCL20 and IL22 Messenger RNA Expression After Adalimumab vs Methotrexate Treatment of Psoriasis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , <b>2015</b> , 151, 837-46	5.1	30
139	Common clonal origin of central and resident memory T cells following skin immunization. <i>Nature Medicine</i> , <b>2015</b> , 21, 647-53	50.5	189
138	Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 116-124.e7	11.5	182
137	Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 208-11	11.5	57
136	Aurora Kinase A Is Upregulated in Cutaneous T-Cell Lymphoma and Represents a Potential Therapeutic Target. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 2292-2300	4.3	20
135	RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 1218-27	11.5	154

134	The Characterization of Varicella Zoster Virus-Specific T Cells in Skin and Blood during Aging. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 1752-1762	4.3	60
133	Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 941-951.e3	11.5	138
132	TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 308ra158	17.5	116
131	The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1254-64	11.5	308
130	Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1277-87	11.5	132
129	Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 934-44	9.5	74
128	Dendritic cells are contained within melanocytic nevus nests in vivo and can alter gene expression of epidermal melanocytes in vitro. <i>Pigment Cell and Melanoma Research</i> , <b>2015</b> , 28, 110-3	4.5	2
127	The immunopathogenesis of psoriasis. <i>Dermatologic Clinics</i> , <b>2015</b> , 33, 13-23	4.2	204
126	Reply: To PMID 25748064. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1707-1708	11.5	
125	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , <b>2015</b> , 173, 930-9	4	186
124	Unique microRNAs appear at different times during the course of a delayed-type hypersensitivity reaction in human skin. <i>Experimental Dermatology</i> , <b>2015</b> , 24, 953-7	4	12
123	Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. <i>BMC Medical Genomics</i> , <b>2015</b> , 8, 60	3.7	88
122	Histological Stratification of Thick and Thin Plaque Psoriasis Explores Molecular Phenotypes with Clinical Implications. <i>PLoS ONE</i> , <b>2015</b> , 10, e0132454	3.7	15
121	A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142081	3.7	49
120	An autoimmune "attack" on melanocytes triggers psoriasis and cellular hyperplasia. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 2186	16.6	20
119	Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 153-63	11.5	127
118	Laser capture microdissection followed by next-generation sequencing identifies disease-related microRNAs in psoriatic skin that reflect systemic microRNA changes in psoriasis. <i>Experimental Dermatology</i> , <b>2015</b> , 24, 187-93	4	43
117	Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 712-20	11.5	44

116	Humanized anti-IFN- $\gamma$ (HuZAF) in the treatment of psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 553-6	11.5	69
115	The translational revolution and use of biologics in patients with inflammatory skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 324-36	11.5	141
114	Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. <i>F1000Research</i> , <b>2015</b> , 4, 149	3.6	10
113	Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. <i>F1000Research</i> , <b>2015</b> , 4, 460	3.6	33
112	Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. <i>Journal of Immunology</i> , <b>2014</b> , 192, 3828-36	5.3	97
111	Gene expression profiling of the leading edge of cutaneous squamous cell carcinoma: IL-24-driven MMP-7. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 1418-1427	4.3	45
110	Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis recurrence. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 955-7	11.5	20
109	IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2990-2993	4.3	40
108	Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 362-72	11.5	167
107	Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 1032-40	11.5	222
106	Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2014</b> , 2, 371-9; quiz 380-1	5.4	116
105	IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. <i>PLoS ONE</i> , <b>2014</b> , 9, e90284	3.7	115
104	Molecular characterization of human skin response to diphenacyprone at peak and resolution phases: therapeutic insights. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 2531-2540	4.3	30
103	Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 87-95	4.3	76
102	Dermal clusters of mature dendritic cells and T cells are associated with the CCL20/CCR6 chemokine system in chronic psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2014</b> , 134, 1462-1465	4.3	53
101	Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5507-16	12.9	44
100	IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 890-900	12.5	16
99	Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 1293-1300	11.5	290

98	Immunology of psoriasis. <i>Annual Review of Immunology</i> , <b>2014</b> , 32, 227-55	34.7	891
97	The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 17-26	4.3	288
96	IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 2741-2752	4.3	116
95	The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. <i>Trends in Immunology</i> , <b>2013</b> , 34, 174-81	14.4	317
94	Gene profiling of narrowband UVB-induced skin injury defines cellular and molecular innate immune responses. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 692-701	4.3	34
93	Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 361-70	11.5	290
92	Creation of differentiation-specific genomic maps of human epidermis through laser capture microdissection. <i>Journal of Investigative Dermatology</i> , <b>2013</b> , 133, 2640-2642	4.3	13
91	IL-17 targeted therapies for psoriasis. <i>Expert Opinion on Investigational Drugs</i> , <b>2013</b> , 22, 993-1005	5.9	114
90	Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation. <i>PLoS ONE</i> , <b>2013</b> , 8, e84634	3.7	80
89	Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 130, 1344-54	11.5	525
88	Hiding under the skin: A welcome surprise in psoriasis. <i>Nature Medicine</i> , <b>2012</b> , 18, 1750-1	50.5	40
87	IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 130, 145-54.e9	11.5	260
86	Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1181-9	59.2	755
85	Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2552-64	4.3	187
84	Post-therapeutic relapse of psoriasis after CD11a blockade is associated with T cells and inflammatory myeloid DCs. <i>PLoS ONE</i> , <b>2012</b> , 7, e30308	3.7	23
83	Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. <i>PLoS ONE</i> , <b>2012</b> , 7, e44274	3.7	126
82	Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1615-26	4.3	58
81	A single intradermal injection of IFN- $\gamma$ induces an inflammatory state in both non-lesional psoriatic and healthy skin. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1177-87	4.3	77

80	Human keratinocytes response to injury upregulates CCL20 and other genes linking innate and adaptive immunity. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 105-113	4.3	83
79	Putting together the psoriasis puzzle: an update on developing targeted therapies. <i>DMM Disease Models and Mechanisms</i> , <b>2012</b> , 5, 423-33	4.1	93
78	Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 2466-2469	4.3	107
77	Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 246-9	4.3	67
76	Gene Expression Profiling Associated with the Progression of Classic Kaposi's Sarcoma. <i>European Journal of Inflammation</i> , <b>2012</b> , 10, 371-382	0.3	1
75	Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 954-64.e1-4	11.5	282
74	Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 1110-8	11.5	236
73	Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 1420-32	11.5	222
72	Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 583-93.e1-4	11.5	143
71	Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 574-82.e1-12	11.5	86
70	Th17 cells and activated dendritic cells are increased in vitiligo lesions. <i>PLoS ONE</i> , <b>2011</b> , 6, e18907	3.7	100
69	Anti-cytokine therapies for psoriasis. <i>Experimental Cell Research</i> , <b>2011</b> , 317, 1293-300	4.2	42
68	Resolved psoriasis lesions retain expression of a subset of disease-related genes. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 391-400	4.3	129
67	Integrative responses to IL-17 and TNF- $\alpha$ in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 677-87	4.3	410
66	Tumor-Associated Macrophages in the Cutaneous SCC Microenvironment Are Heterogeneously Activated. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 1322-1330	4.3	107
65	Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. <i>Journal of Investigative Dermatology</i> , <b>2011</b> , 131, 1322-30	4.3	73
64	A subpopulation of CD163-positive macrophages is classically activated in psoriasis. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 2412-22	4.3	191
63	UV radiation inhibits 15-hydroxyprostaglandin dehydrogenase levels in human skin: evidence of transcriptional suppression. <i>Cancer Prevention Research</i> , <b>2010</b> , 3, 1104-11	3.2	14

62	Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). <i>PLoS ONE</i> , <b>2010</b> , 5, e10247	3.7	125
61	Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 2654-63	4.3	110
60	Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, 1261-1268.e9	11.5	83
59	New insights in the immunologic basis of psoriasis. <i>Seminars in Cutaneous Medicine and Surgery</i> , <b>2010</b> , 29, 3-9	1.4	138
58	Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 1785-96	4.3	447
57	Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 21795-800	11.5	204
56	Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. <i>Journal of Clinical Immunology</i> , <b>2009</b> , 29, 247-56	5.7	81
55	Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 79-88	4.3	305
54	Resident and "inflammatory" dendritic cells in human skin. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 302-8	4.3	232
53	Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. <i>Journal of Investigative Dermatology</i> , <b>2009</b> , 129, 2451-62	4.3	52
52	IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 123, 1244-52.e2	11.5	466
51	Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 124, 1022-10.e1-395	11.5	241
50	Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 2615-2624	4.3	21
49	Insights into gene modulation by therapeutic TNF and IFN $\gamma$ antibodies: TNF regulates IFN $\gamma$ production by T cells and TNF-regulated genes linked to psoriasis transcriptome. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 655-66	4.3	28
48	Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 1207-11	4.3	757
47	Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. <i>British Journal of Dermatology</i> , <b>2008</b> , 159, 1092-102	4	561
46	Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness. <i>Journal of Investigative Dermatology</i> , <b>2008</b> , 128, 1182-91	4.3	47
45	Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. <i>Journal of Immunology</i> , <b>2008</b> , 180, 1913-20	5.3	143



44	Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. <i>Journal of Immunology</i> , <b>2008</b> , 181, 7420-7	5.3	265
43	Type I interferon: potential therapeutic target for psoriasis?. <i>PLoS ONE</i> , <b>2008</b> , 3, e2737	3.7	209
42	Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin. <i>Blood</i> , <b>2008</b> , 112, 4350-4350	2.2	
41	Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. <i>Journal of Translational Medicine</i> , <b>2007</b> , 5, 27	8.5	52
40	Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2007</b> , 119, 1210-7	11.5	174
39	Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series. <i>BMC Dermatology</i> , <b>2007</b> , 7, 2	2.1	14
38	Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. <i>Journal of Investigative Dermatology</i> , <b>2007</b> , 127, 2391-8	4.3	86
37	Pathogenesis and therapy of psoriasis. <i>Nature</i> , <b>2007</b> , 445, 866-73	50.4	1292
36	Psoriasis: evolution of pathogenic concepts and new therapies through phases of translational research. <i>British Journal of Dermatology</i> , <b>2007</b> , 157, 1103-15	4	48
35	Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. <i>Journal of Experimental Medicine</i> , <b>2007</b> , 204, 3183-94	16.6	522
34	Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIa+ macrophages. <i>Journal of Clinical Investigation</i> , <b>2007</b> , 117, 2517-25	15.9	239
33	Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 869-81	4.3	143
32	Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. <i>Journal of Investigative Dermatology</i> , <b>2006</b> , 126, 1590-9	4.3	72
31	Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series. <i>BMC Dermatology</i> , <b>2005</b> , 5, 9	2.1	23
30	Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 19057-62	11.5	382
29	Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 2075-80	11.5	187
28	Psoriasis genomics: analysis of proinflammatory (type 1) gene expression in large plaque (Western) and small plaque (Asian) psoriasis vulgaris. <i>British Journal of Dermatology</i> , <b>2004</b> , 150, 668-76	4	51
27	Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. <i>Journal of Experimental Medicine</i> , <b>2004</b> , 199, 125-30	16.6	712

26	Current concepts in the immunopathogenesis of psoriasis. <i>Dermatologic Clinics</i> , <b>2004</b> , 22, 349-69, vii	4.2	38
25	Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. <i>Clinical Immunology</i> , <b>2004</b> , 113, 38-46	9	64
24	Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. <i>Trends in Immunology</i> , <b>2004</b> , 25, 295-305	14.4	226
23	Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. <i>Physiological Genomics</i> , <b>2003</b> , 13, 69-78	3.6	248
22	The immunologic basis for the treatment of psoriasis with new biologic agents. <i>Journal of the American Academy of Dermatology</i> , <b>2002</b> , 46, 1-23; quiz 23-6	4.5	456
21	Potential role of the chemokine receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogenesis of psoriasis vulgaris. <i>Laboratory Investigation</i> , <b>2001</b> , 81, 335-47	5.9	190
20	Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. <i>Journal of Experimental Medicine</i> , <b>2000</b> , 192, 681-94	16.6	273
19	CD69, HLA-DR and the IL-2R identify persistently activated T cells in psoriasis vulgaris lesional skin: blood and skin comparisons by flow cytometry. <i>Journal of Autoimmunity</i> , <b>2000</b> , 14, 63-78	15.5	119
18	Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 42, 428-35	4.5	175
17	Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?. <i>Journal of the American Academy of Dermatology</i> , <b>2000</b> , 43, 281-5	4.5	174
16	The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. <i>Journal of Investigative Dermatology</i> , <b>1999</b> , 113, 752-9	4.3	360
15	312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. <i>Journal of Experimental Medicine</i> , <b>1999</b> , 189, 711-8	16.6	250
14	CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 103, 1243-52	15.9	463
13	Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions. <i>Journal of Clinical Investigation</i> , <b>1999</b> , 104, 1527-37	15.9	160
12	Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TIA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis. <i>Journal of Cutaneous Pathology</i> , <b>1998</b> , 25, 79-88	1.7	53
11	Identification of aberrantly regulated genes in diseased skin using the cDNA differential display technique. <i>Journal of Investigative Dermatology</i> , <b>1997</b> , 108, 188-94	4.3	56
10	Identification of a novel keratinocyte mitogen derived from bovine pituitary glands. <i>Archives of Dermatological Research</i> , <b>1997</b> , 289, 309-16	3.3	3
9	PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. <i>Photochemistry and Photobiology</i> , <b>1996</b> , 63, 566-71	3.6	88

8	In vivo expression of the insulin-like growth factor-I (IGF-I) receptor in congenital pigmented nevi. <i>Journal of Cutaneous Pathology</i> , <b>1996</b> , 23, 19-24	1.7	4
7	Modulation of epidermal differentiation, tissue inflammation, and T-lymphocyte infiltration in psoriatic plaques by topical calcitriol. <i>Journal of Cutaneous Pathology</i> , <b>1996</b> , 23, 419-30	1.7	22
6	Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. <i>Nature Medicine</i> , <b>1995</b> , 1, 442-7	50.5	548
5	Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. <i>Journal of Investigative Dermatology</i> , <b>1992</b> , 98, 302-9	4.3	84
4	Fixed drug eruptions: evidence for a cytokine-mediated process. <i>Journal of Cutaneous Pathology</i> , <b>1991</b> , 18, 13-9	1.7	23
3	Increased dermal expression of platelet-derived growth factor receptors in growth-activated skin wounds and psoriasis. <i>Journal of Investigative Dermatology</i> , <b>1991</b> , 96, 983-6	4.3	41
2	Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. <i>Journal of Investigative Dermatology</i> , <b>1990</b> , 94, 135S-140S	4.3	187
1	Type I interferon modulates Langerhans cell ADAM17 to promote photosensitivity in lupus		1